Women with advanced or recurring ovarian, peritoneal, or fallopian tube cancer may be eligible to participate in a new clinical trial offered by Sarasota Memorial’s Kolschowsky Research and Education Institute.
In 2025, roughly 313,780 men in the US will learn they have prostate cancer and 35,770 will die from it. Since 2014, that rate has only been increasing. But a new targeted therapy called Pluvicto is changing the game.
